Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.37 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | HGFAC | Q04756 | 1/20 | 0.34 |
| ▸ | ESR1 | P03372 | 1/20 | 0.34 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15928900 | 0.91 | KMT2A (0.42) | KMT2AALDH1A1TSHRHSD17B10PTGS2 | |
| SCHEMBL15928965 | 0.91 | KMT2A (0.38) | KMT2AALDH1A1TSHRHSD17B10PTGS2 | |
| SCHEMBL15928839 | 0.91 | KMT2A (0.38) | KMT2AALDH1A1TSHRHSD17B10PTGS2 | |
| SCHEMBL15928842 | 0.85 | CA12 (0.45) | KMT2AALDH1A1TSHRHSD17B10PTGS2 | |
| SCHEMBL20871763 | 0.84 | PTGS2 (0.43) | KMT2AALDH1A1TSHRHSD17B10PTGS2 | |
| SCHEMBL15928983 | 0.82 | HDAC3 (0.39) | KMT2AALDH1A1TSHRHSD17B10PTGS2 | |
| SCHEMBL15928966 | 0.82 | KMT2A (0.41) | KMT2AALDH1A1TSHRHSD17B10PTGS2 | |
| SCHEMBL15928961 | 0.82 | KMT2A (0.41) | KMT2AALDH1A1TSHRHSD17B10PTGS2 | |
| Ncx-4016 SCHEMBL29813476 | 0.80 | PTGS2 (0.57) | KMT2AALDH1A1TSHRHSD17B10PTGS2 | |
| Ncx-4016 SCHEMBL29546681 | 0.80 | PTGS2 (0.57) | KMT2AALDH1A1TSHRHSD17B10PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10450260-B2 | NO- and H2S-releasing compounds | RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK (US) | 2019-10-22 | — | — | US | disclosed |
| US-20170260124-A1 | NO- AND H2S- RELEASING COMPOUNDS | RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK | 2017-09-14 | — | — | US | disclosed |
| US-9688607-B2 | No- and H2S-releasing compounds | RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK (US) | 2017-06-27 | — | — | US | disclosed |
| US-20170174651-A1 | Method of Priming Plants Against Abiotic Stress Factors | CYPRUS UNIVERSITY OF TECHNOLOGY (CY) | 2017-06-22 | — | — | US | disclosed |
| US-20140221316-A1 | NO- AND H2S- RELEASING COMPOUNDS | RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK (US) | 2014-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140221316-A1 | NO- AND H2S- RELEASING COMPOUNDS | PTGS1, NOS2, NOS1 | KMT2A 3325/4885ALDH1A1 363/4885TSHR 2979/4885 |
| US-20170260124-A1 | NO- AND H2S- RELEASING COMPOUNDS | NOS2, NOS3, NOS1 | KMT2A 2955/4885ALDH1A1 961/4885TSHR 2112/4885 |
| US-10450260-B2 | NO- and H2S-releasing compounds | NOS2, NOS3, NOS1 | KMT2A 2955/4885ALDH1A1 961/4885TSHR 2112/4885 |
| US-20170174651-A1 | Method of Priming Plants Against Abiotic Stress Factors | NOS2, NOS1, HSF1 | KMT2A 3818/4885ALDH1A1 3155/4885TSHR 3827/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.